Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen Placarbil in GERD Incomplete Responders
NCT00978016Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- Sep 2009
- Primary completion
- Dec 2010
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of arbaclofen placarbil in gastroesophageal reflux disease (GERD), sponsored by XenoPort, Inc.. Started Sep 2009; status: completed.
02
Drugs
arbaclofen placarbil
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00978016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00978016.